Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Leif Dahllund"'
Autor:
Benjamin Weinkauf, Roman Rukwied, Hans Quiding, Leif Dahllund, Patrick Johansson, Martin Schmelz
Publikováno v:
PLoS ONE, Vol 7, Iss 6, p e39411 (2012)
UV-irradiation is a well-known translational pain model inducing local inflammation and primary hyperalgesia. The mediators and receptor proteins specifically contributing to mechanical or heat hyperalgesia are still unclear. Therefore, we irradiated
Externí odkaz:
https://doaj.org/article/03b860495d654114885c9df5e5374dd7
Autor:
Pål Stenmark, Thomas Helleday, Evert Homan, Yasmin Andersson, Martin Henriksson, Maria Häggblad, Sabin Llona-Minguez, Leif Dahllund, Nadilly Bonagas, Elisée Wiita, Olga Loseva, Katarina Färnegårdh, Nina M.S. Gustafsson, Ann-Sofie Jemth, Robert Gustafsson
Buffers for MTHFD2 and MTHFD1 DC-domain lysis, purification and inhibition assay.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b582a3653a74d99a229e83fd3a02ea1e
https://doi.org/10.1158/0008-5472.22414455
https://doi.org/10.1158/0008-5472.22414455
Autor:
Pål Stenmark, Thomas Helleday, Evert Homan, Yasmin Andersson, Martin Henriksson, Maria Häggblad, Sabin Llona-Minguez, Leif Dahllund, Nadilly Bonagas, Elisée Wiita, Olga Loseva, Katarina Färnegårdh, Nina M.S. Gustafsson, Ann-Sofie Jemth, Robert Gustafsson
Description of additional methods and procedures used in the study. Also includes Supplementary References.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0bc9eb2d0df2cb71d1f9ae89c01980c
https://doi.org/10.1158/0008-5472.22414458
https://doi.org/10.1158/0008-5472.22414458
Autor:
Pål Stenmark, Thomas Helleday, Evert Homan, Yasmin Andersson, Martin Henriksson, Maria Häggblad, Sabin Llona-Minguez, Leif Dahllund, Nadilly Bonagas, Elisée Wiita, Olga Loseva, Katarina Färnegårdh, Nina M.S. Gustafsson, Ann-Sofie Jemth, Robert Gustafsson
To sustain their proliferation, cancer cells become dependent on one-carbon metabolism to support purine and thymidylate synthesis. Indeed, one of the most highly upregulated enzymes during neoplastic transformation is MTHFD2, a mitochondrial methyle
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::27b1c130815606c4da40d07eee51a98b
https://doi.org/10.1158/0008-5472.c.6508983.v1
https://doi.org/10.1158/0008-5472.c.6508983.v1
Autor:
Nadilly Bonagas, Nina M. S. Gustafsson, Martin Henriksson, Petra Marttila, Robert Gustafsson, Elisée Wiita, Sanjay Borhade, Alanna C. Green, Karl S. A. Vallin, Antonio Sarno, Richard Svensson, Camilla Göktürk, Therese Pham, Ann-Sofie Jemth, Olga Loseva, Victoria Cookson, Nicole Kiweler, Lars Sandberg, Azita Rasti, Judith E. Unterlass, Martin Haraldsson, Yasmin Andersson, Emma R. Scaletti, Christoffer Bengtsson, Cynthia B. J. Paulin, Kumar Sanjiv, Eldar Abdurakhmanov, Linda Pudelko, Ben Kunz, Matthieu Desroses, Petar Iliev, Katarina Färnegårdh, Andreas Krämer, Neeraj Garg, Maurice Michel, Sara Häggblad, Malin Jarvius, Christina Kalderén, Amanda Bögedahl Jensen, Ingrid Almlöf, Stella Karsten, Si Min Zhang, Maria Häggblad, Anders Eriksson, Jianping Liu, Björn Glinghammar, Natalia Nekhotiaeva, Fredrik Klingegård, Tobias Koolmeister, Ulf Martens, Sabin Llona-Minguez, Ruth Moulson, Helena Nordström, Vendela Parrow, Leif Dahllund, Birger Sjöberg, Irene L. Vargas, Duy Duc Vo, Johan Wannberg, Stefan Knapp, Hans E. Krokan, Per I. Arvidsson, Martin Scobie, Johannes Meiser, Pål Stenmark, Ulrika Warpman Berglund, Evert J. Homan, Thomas Helleday
Publikováno v:
Nature Cancer
The folate metabolism enzyme MTHFD2 (methylenetetrahydrofolate dehydrogenase/cyclohydrolase) is consistently overexpressed in cancer but its roles are not fully characterized, and current candidate inhibitors have limited potency for clinical develop
Autor:
Nadilly Bonagas, Nina Gustafsson, Martin Henriksson, Petra Marttila, Robert Gustafsson, Elisée Wiita, Sanjay Borhade, Alanna Green, Karl Vallin, Antonio Sarno, Richard Svensson, Camilla Göktürk, Therese Pham, Ann-Sofie Jemth, Olga Loseva, Victoria Cookson, Nicole Kiweler, Lars Sandberg, Azita Rasti, Judith Unterlass, Martin Haraldsson, Yasmin Andersson, Emma Scaletti, Christoffer Bengtsson, Cynthia Paulin, Kumar Sanjiv, Eldar Abdurakhmanov, Linda Pudelko, Ben Kunz, Matthieu Desroses, Petar Iliev, Katarina Färnegårdh, Andreas Krämer, Neeraj Garg, Maurice Michel, Sara Häggblad, Malin Jarvius, Christina Kalderén, Amanda Bögedahl Jensen, Ingrid Almlöf, Stella Karsten, Si Min Zhang, Maria Häggblad, Anders Eriksson, Jianping Liu, Björn Glinghammar, Natalia Nekhotiaeva, Fredrik Klingegård, Tobias Koolmeister, Ulf Martens, Sabin Llona-Minguez, Ruth Moulson, Helena Nordström, Vendela Parrow, Leif Dahllund, Birger Sjöberg, Irene Vargas, Duy Duc Vo, Johan Wannberg, Stefan Knapp, Hans Krokan, Per Arvidsson, Martin Scobie, Johannes Meiser, Pål Stenmark, Ulrika Warpman Berglund, Evert Homan, Thomas Helleday
Supplementary methods for the article "Pharmacological targeting of MTHFD2 suppresses acute myeloid leukemia by inducing thymidine depletion and replication stress".
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::032514cb5181fdda8fdfefd73848c5d0
https://doi.org/10.21203/rs.3.pex-1730/v1
https://doi.org/10.21203/rs.3.pex-1730/v1
Autor:
Ida Laurén, Mohamed Eltahir, Aman Mebrahtu, Rosanne Veerman, Juan Astorga, Aljona Saleh, Jimmy Ytterberg, Annika Lindqvist, Leif Dahllund, Anders Olsson, Oskar Andersson, Johan Rockberg, Helena Persson, Sara Mangsbo
Publikováno v:
Cancer Research. 82:2890-2890
CD40 agonistic antibodies targeting antigen-presenting cells rely on simultaneous antigen presentation for optimal efficacy, as the co-stimulatory signal alone will not lead to T cell activation. Herein we have developed a novel Adaptable Drug Affini
Autor:
Mohamed Eltahir, Ida Laurén, Martin Lord, Aikaterini Chourlia, Leif Dahllund, Anders Olsson, Aljona Saleh, A. Jimmy Ytterberg, Annika Lindqvist, Oskar Andersson, Helena Persson, Sara M. Mangsbo
Publikováno v:
Advanced Therapeutics. 5:2200008
The agonistic potentials of therapeutic anti-CD40 antibodies have been profiled in relation to antibody isotype and epitope specificity. Still, clinical impact relies on a well-balanced clinical efficacy versus target-mediated toxicity. As CD40-media
Autor:
Martin Lord, Greta Hultqvist, Triinu Linkgreim, Sara M. Mangsbo, Leif Dahllund, Oskar Andersson, Helena Persson, Martin Hall, Anders Olsson, Peter Frank, Annika Morrison, Andreas Andersson, Ida Laurén, Antonino Napoleone
The transition from preclinical biological drug development into clinical trials requires an efficient upscaling process. In this context, bispecific antibody drugs are particularly challenging due to their propensity to form aggregates and generally
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b3c5d0c6ac3a8406e91b0880961c7bb
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-456001
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-456001
Autor:
Sabin Llona-Minguez, Katarina Färnegårdh, Leif Dahllund, Maria Häggblad, Nina M. S. Gustafsson, Yasmin Andersson, Pål Stenmark, Nadilly Bonagas, Ann-Sofie Jemth, Thomas Helleday, Olga Loseva, Elisee Wiita, Robert Gustafsson, Martin Henriksson, Evert Homan
Publikováno v:
Cancer Research. 77:937-948
To sustain their proliferation, cancer cells become dependent on one-carbon metabolism to support purine and thymidylate synthesis. Indeed, one of the most highly upregulated enzymes during neoplastic transformation is MTHFD2, a mitochondrial methyle